Continuing its recent strong investment in the area of oncology, French privately-held company Pierre Fabre has inked a new drug discovery deal with British firm Vernalis.
A fully-owned subsidiary of HitGen, Vernalis uses a combination of approaches, leveraging structural biology, biophysics and molecular modeling, among other things.
The firm is focused on drug discovery for both established and novel targets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze